Edoxaban vs Apixaban: Efficacy and Side Effects
For stroke prevention in atrial fibrillation, apixaban demonstrates superior safety with lower major bleeding risk compared to edoxaban, while both agents show similar efficacy for preventing stroke and systemic embolism. 1, 2
Efficacy Comparison
Stroke Prevention
Both agents are effective for stroke prevention in AF, with no clinically meaningful difference in preventing ischemic stroke or systemic embolism when compared head-to-head in real-world studies 3, 4. The 2024 ESC guidelines confirm that all DOACs (including both edoxaban and apixaban) reduce stroke/systemic embolism by approximately 19% compared to warfarin, with this benefit primarily driven by reduction in hemorrhagic stroke 1.
However, one recent Italian real-world study of 8,444 patients found edoxaban had 22% lower risk of stroke/systemic embolism compared to apixaban (HR 0.78,95% CI 0.61-0.99), particularly in patients ≥80 years old 3. This finding contradicts other studies and requires cautious interpretation given the observational design.
Mortality
Both apixaban and edoxaban demonstrated mortality benefits over warfarin in their pivotal trials 5. Apixaban showed 11% reduction in all-cause mortality in ARISTOTLE 6, 7, while edoxaban's lower dose showed mortality benefit in ENGAGE AF-TIMI 48 8, 5.
Safety Profile: The Critical Differentiator
Major Bleeding Risk
Apixaban consistently demonstrates lower major bleeding rates compared to edoxaban across multiple studies 2, 9. This is the most clinically significant difference between these agents:
- In the UK elderly population study (≥80 years), edoxaban had 42% higher major bleeding risk (adjusted HR 1.42,95% CI 1.26-1.61) compared to apixaban 2
- Both agents reduce intracranial hemorrhage by approximately 50% compared to warfarin 1, 5
- Apixaban had significantly less major or clinically relevant non-major bleeding compared to edoxaban in indirect comparisons 10
Gastrointestinal Bleeding
Apixaban shows lower gastrointestinal bleeding rates compared to edoxaban in indirect analyses (HR 0.72,95% CI 0.53-0.99) 10. This is particularly relevant for elderly patients at higher baseline GI bleeding risk.
Dosing Considerations
Apixaban Dosing 1, 7
- Standard dose: 5 mg twice daily
- Reduced dose: 2.5 mg twice daily if patient meets ≥2 of these criteria:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (133 μmol/L)
Edoxaban Dosing 1
- Standard dose: 60 mg once daily
- Reduced dose: 30 mg once daily if ANY of:
- CrCl 30-50 mL/min
- Body weight ≤60 kg
- Concomitant verapamil, quinidine, or dronedarone
Critical caveat: Edoxaban is NOT recommended for CrCl >95 mL/min due to reduced efficacy in the ENGAGE AF-TIMI 48 trial 8. This is a unique contraindication not shared by apixaban.
Special Populations
Elderly Patients (≥80 years)
Apixaban is preferred in very elderly patients due to superior safety profile 2, 11. The UK study specifically in patients ≥80 years showed edoxaban had similar thromboembolism prevention but significantly higher major bleeding (45.57 vs 31.21 per 1000 person-years) 2.
Renal Impairment
- Apixaban is preferred in dialysis-dependent patients 8, 12. Edoxaban is 50% renally excreted and NOT recommended in end-stage renal disease or dialysis 8
- For CKD stage 4-5, apixaban can be used with dose adjustment, while edoxaban should be avoided 12, 13
Frailty
Apixaban demonstrates the most favorable benefit-risk profile in frail elderly patients 11. The combination of lower bleeding risk and twice-daily dosing (which may improve adherence monitoring) makes it preferable in this vulnerable population.
Clinical Algorithm for Selection
Choose Apixaban if:
- Age ≥80 years (superior safety) 2
- High bleeding risk (lower major bleeding) 9, 10
- CrCl <30 mL/min or on dialysis (only DOAC with data) 8, 12
- Frailty present 11
- Prior GI bleeding (lower GI bleeding risk) 10
Choose Edoxaban if:
- Patient preference for once-daily dosing
- CrCl 30-95 mL/min (within approved range)
- Cost considerations (may vary by region)
- No high bleeding risk factors
Avoid Edoxaban if:
- CrCl >95 mL/min (reduced efficacy) 8
- CrCl <30 mL/min or dialysis-dependent 8
- Very elderly (≥80 years) with bleeding risk factors 2
Common Pitfalls
- Underdosing: Using reduced-dose DOAC without meeting specific criteria increases stroke risk without reducing bleeding 1, 13
- Ignoring renal function: Edoxaban in high CrCl (>95 mL/min) reduces efficacy; failure to monitor renal function leads to inappropriate dosing 8
- Switching stable elderly patients: The FRAIL-AF trial showed switching stable elderly patients from warfarin to DOACs increased early bleeding risk 11
- Overlooking drug interactions: Edoxaban requires dose reduction with verapamil, quinidine, or dronedarone 1